Cited 51 times in
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.contributor.author | 최은창 | - |
dc.contributor.author | 고윤우 | - |
dc.contributor.author | 권형주 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 김한상 | - |
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 백순명 | - |
dc.contributor.author | 이민구 | - |
dc.contributor.author | 이지현 | - |
dc.contributor.author | 정인경 | - |
dc.date.accessioned | 2016-02-04T10:57:34Z | - |
dc.date.available | 2016-02-04T10:57:34Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139356 | - |
dc.description.abstract | PURPOSE: The goals of this study were to investigate the clinical activity, safety, and biomarkers of dacomitinib, an irreversible tyrosine kinase inhibitor of EGFR, HER2, and HER4, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). EXPERIMENTAL DESIGN: Patients were eligible if the diseases were not amenable to curative treatment and had progressed on platinum-based chemotherapy, and were treated with dacomitinib 45 mg/day. The primary endpoint was objective response rate by RECISTv1.1. Exploratory analysis included the characterization of somatic mutation, gene copy number, gene expression, p16(INK4A) expression by IHC, and investigation of their relationship with clinical outcomes. RESULTS: Forty-eight patients were evaluable for efficacy and toxicity. Ten patients (20.8%) had partial responses and 31 patients (65%) had stable diseases. The median progression-free survival (PFS) and overall survival (OS) were 3.9 months [95% confidence interval (CI), 2.9-5.0] and 6.6 months (95% CI, 5.4-10.3). Adverse events were mostly grade 1-2. Mutations in the PI3K pathway (PIK3CA, PTEN) and high expression of inflammatory cytokines (IL6, IL8, IL1A, IL1B, IL4, and TNF) were significantly associated with shorter PFS (2.9 vs. 4.9 months without mutations, P = 0.013; 2.8 vs. 9.9 months with low expression, P = 0.004). Those harboring PI3K pathway mutations or high inflammatory cytokine expression had shorter median OS (6.1 vs. 12.5 months lacking PI3K pathway mutations and with low inflammatory cytokine expression, P = 0.005). CONCLUSIONS: Dacomitinib demonstrated clinical efficacy with manageable toxicity in platinum-failed R/M-SCCHN patients. Screening of PI3K pathway mutation and inflammatory cytokine expression may help identify which R/M-SCCHN patients are likely to gain benefit from dacomitinib. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Biomarkers | - |
dc.subject.MESH | Carcinoma, Squamous Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/genetics | - |
dc.subject.MESH | Carcinoma, Squamous Cell/mortality | - |
dc.subject.MESH | Carcinoma, Squamous Cell/pathology* | - |
dc.subject.MESH | Cluster Analysis | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Dosage | - |
dc.subject.MESH | Gene Expression Profiling | - |
dc.subject.MESH | Head and Neck Neoplasms/drug therapy* | - |
dc.subject.MESH | Head and Neck Neoplasms/genetics | - |
dc.subject.MESH | Head and Neck Neoplasms/mortality | - |
dc.subject.MESH | Head and Neck Neoplasms/pathology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Protein Kinase Inhibitors/administration & dosage | - |
dc.subject.MESH | Protein Kinase Inhibitors/adverse effects | - |
dc.subject.MESH | Protein Kinase Inhibitors/therapeutic use* | - |
dc.subject.MESH | Quinazolinones/administration & dosage | - |
dc.subject.MESH | Quinazolinones/adverse effects | - |
dc.subject.MESH | Quinazolinones/therapeutic use* | - |
dc.subject.MESH | Retreatment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Life Science (의생명과학부) | - |
dc.contributor.googleauthor | Han Sang Kim | - |
dc.contributor.googleauthor | Hyeong Ju Kwon | - |
dc.contributor.googleauthor | Inkyung Jung | - |
dc.contributor.googleauthor | Mi Ran Yun | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Byung Woog Kang | - |
dc.contributor.googleauthor | Jong-Mu Sun | - |
dc.contributor.googleauthor | Sung Bae Kim | - |
dc.contributor.googleauthor | Dok-Hyun Yoon | - |
dc.contributor.googleauthor | Keon Uk Park | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Yoon Woo Koh | - |
dc.contributor.googleauthor | Se Hun Kim | - |
dc.contributor.googleauthor | Eun Chang Choi | - |
dc.contributor.googleauthor | Dong Hoe Koo | - |
dc.contributor.googleauthor | Jin Hee Sohn | - |
dc.contributor.googleauthor | Bomi Kim | - |
dc.contributor.googleauthor | Nak-Jung Kwon | - |
dc.contributor.googleauthor | Hwan Jung Yun | - |
dc.contributor.googleauthor | Min Goo Lee | - |
dc.contributor.googleauthor | Ji Hyun Lee | - |
dc.contributor.googleauthor | Tae-Min Kim | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.contributor.googleauthor | Soonmyung Paik | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-14-1756 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04161 | - |
dc.contributor.localId | A00133 | - |
dc.contributor.localId | A00264 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A01823 | - |
dc.contributor.localId | A02781 | - |
dc.contributor.localId | A03693 | - |
dc.contributor.localId | A01098 | - |
dc.contributor.localId | A03214 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 25424851 | - |
dc.identifier.url | http://clincancerres.aacrjournals.org/content/21/3/544.long | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Choi, Eun Chang | - |
dc.contributor.alternativeName | Kho, Yoon Woo | - |
dc.contributor.alternativeName | Kwon, Hyeong Ju | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Kim, Han Sang | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Paik, Soon Myung | - |
dc.contributor.alternativeName | Lee, Min Goo | - |
dc.contributor.alternativeName | Lee, Ji Hyun | - |
dc.contributor.alternativeName | Jung, In Kyung | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Eun Chang | - |
dc.contributor.affiliatedAuthor | Kho, Yoon Woo | - |
dc.contributor.affiliatedAuthor | Kwon, Hyeong Ju | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Paik, Soon Myung | - |
dc.contributor.affiliatedAuthor | Lee, Min Goo | - |
dc.contributor.affiliatedAuthor | Jung, In Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Han Sang | - |
dc.contributor.affiliatedAuthor | Lee, Ji Hyun | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 21 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 544 | - |
dc.citation.endPage | 552 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.21(3) : 544-552, 2015 | - |
dc.identifier.rimsid | 39398 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.